ArticleNature communications2019
Type I-F CRISPR-Cas resistance against virulent phages results in abortive infection and provides population-level immunity.
Article in Nature communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed.
- Structural Receptors and Host Adaptations Affecting the Bacteriophage Targeting ofMicroorganisms · 2026Review
- Bacterial immune systems.Antonie van Leeuwenhoek · 2026Review
- Comparative Genomic and Functional Characterization of Two Lytic Bacteriophages Against Antimicrobial-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Bacterial Schlafen proteins mediate phage defence.Nature microbiology · 2026Article
- Pharmacological evaluation of phage-antibiotic synergism against clinical isolates of multi-drug resistant Staphylococcus aureus in a burn-induced infection mouse model.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025Article
- Battle beyond membrane: flagella as a conduit for phage DNA entry and a trigger for bacterial defense in Yersinia enterocolitica.Nucleic acids research · 2025Article
- Phage susceptibility to a minimal, modular synthetic CRISPR-Cas system inPhilosophical transactions of the Royal Society of London. Series B, Biological sciences · 2025Article
- Pseudomonas aeruginosa as a model bacterium in antiphage defense research.FEMS microbiology reviews · 2025Review
- Characterisation of four novel bacteriophages targeting carbapenem-resistantCurrent research in microbial sciences · 2025Article
- Distribution of specific prokaryotic immune systems correlates with host optimal growth temperature.NAR genomics and bioinformatics · 2024Article
- Identification of a lytic bacteriophage against clinical isolates ofVeterinary research forum : an international quarterly journal · 2024Article
- Bacterial defences: mechanisms, evolution and antimicrobial resistance.Nature reviews. Microbiology · 2023Review
- The novel anti-phage system Shield co-opts an RmuC domain to mediate phage defense across Pseudomonas species.PLoS genetics · 2023Article
- Review
- Unveil the Secret of the Bacteria and Phage Arms Race.International journal of molecular sciences · 2023Review
- The diverse arsenal of type III CRISPR-Cas-associated CARF and SAVED effectors.Biochemical Society transactions · 2022Review
- Alternative functions of CRISPR-Cas systems in the evolutionary arms race.Nature reviews. Microbiology · 2022Review
- Single cell variability of CRISPR-Cas interference and adaptation.Molecular systems biology · 2022Article
- Mechanisms and clinical importance of bacteriophage resistance.FEMS microbiology reviews · 2022Review
- Type I CRISPR-Cas provides robust immunity but incomplete attenuation of phage-induced cellular stress.Nucleic acids research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Type I CRISPR-Cas systems are abundant and widespread adaptive immune systems in bacteria and can greatly enhance bacterial survival in the face of phage infection. Upon phage infection, some CRISPR-Cas immune responses result in bacterial dormancy or slowed growth, which suggests the outcomes for infected cells may vary between systems. Here we demonstrate that type I CRISPR immunity of Pectobacterium atrosepticum leads to suppression of two unrelated virulent phages, ɸTE and ɸM1. Immunity results in an abortive infection response, where infected cells do not survive, but viral propagation is severely decreased, resulting in population protection due to the reduced phage epidemic. Our findings challenge the view of CRISPR-Cas as a system that protects the individual cell and supports growing evidence of abortive infection by some types of CRISPR-Cas systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.